Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants
NCT05174013Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3858279 in osteoarthritis (OA) and diabetic polyneuropathy (DPN) (6 arms), sponsored by GSK. Primary endpoints: Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAE's) And Withdrawals Due to AE's up to 169 days, Change From Baseline in Hematology Parameter of Platelet Count at Day 169 and 19 more. Started Feb 2022; status: completed.
02
Drugs
GSK3858279
03
Conditions
osteoarthritis (OA)diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05174013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174013.